YDES
YD Bio Limited Ordinary Shares
NASDAQ · Healthcare · Biotechnology · TW
$3.54
−3.54%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−84.0x
Market Cap
$250.74M
MomentumView details →
1D Return
−3.54%
YTD Return
−70.10%
RSI (14)
51.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−84.0x
Market Cap
$250.74M
RSI (14)
51.4
MomentumView details →
1D Return
−3.54%
YTD Return
−70.10%
Similar companies
Latest newsMore news →
YD Bio Limited announced its unaudited financial results for the six months ended June 30, 2026.4d agoYD Bio, YD Bio US, EG BioMed US, and Numia Health launched a six-month pilot collaboration to evaluate a cross-border clinical workflow for physician-ordered, blood-based cancer testing for patients in British Columbia, Canada.38d agoYD Bio's affiliate EG BioMed US obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its U.S. laboratory footprint to 46 states for DNA-methylation early cancer detection operations.64d ago